Research
Thymoglobulin Use in Liver Transplant Patients
Pharmacodynamics, Pharmacogenomics and Preliminary Safety and Efficacy of rATG Induction and Tacrolimus Monotherapy in Pediatric Liver Transplantation
Protocol Description
This research study is taking a look at a new combination of medicines used in liver transplantation to see how they work to prevent rejection. Traditional combinations of tacrolimus plus steroids can cause suppression of the function of lymphocytes, delayed growth and development of bones. In this study, both the traditional combination and the introduction of thymoglobulin used with tacrolimus in place of steroids will be used.
Eligibility Criteria
Eligible candidates will include males and females, under 21 years of age, who are about to receive a liver transplant.
Males: 21 years and younger
Females: 21 years and younger
Requirements
Participants will undergo various routine procedures for transplant patients, including blood draws, while receiving either the newer combination or the traditional combination of anti-rejection drugs throughout the study duration.
Visits: Multiple, as with conventional post-transplant care
Duration: 1 year
Status: Open for Enrollment
Sources of Support
Genzyme Corporation
National Institutes of Health
Pediatric Transplantation Department, Children’s Hospital of Pittsburgh of UPMC
Primary Investigator(s)
Rakesh Sindhi, MD
Contact Information
To get started, please contact:
Rakesh Sindhi, MD
412-692-6110
